fbpx

Pipeline

PRODUCT CANDIDATES

PLUS THERAPEUTICS is focused on developing innovative, targeted radiotherapeutics for adult and pediatric patients worldwide with rare and difficult-to-treat cancers. These are incurable and often fatal diseases for which there are few good treatment options. PLUS THERAPEUTICS is looking to offer novel treatments with potentially improved safety, efficacy, and convenience to these patients and their healthcare providers.

Our lead product candidate, 186RNL (BMEDA-Chelated Rhenium-186 NanoLiposome) is designed and intended to treat various central nervous system (CNS) tumors. 

186RNL

Central Nervous System (CNS) Tumors

DEVELOPMENT STATUS

Our pipeline is founded upon promising data generated in a variety of preclinical studies and company-sponsored clinical trials.

186RNL (BMEDA-Chelated Rhenium-186 NanoLiposome)

Indication
Delivery
FDA Designations
Funding
Status
Recurrent GlioblastomaIntratumoral+ Fast Track
+ Orphan Drug
NIH/NCIReSPECT-GBM Phase 1 Clinical Trial (Enrolling)
Leptomeningeal MetastasesIntrathecal+ Fast Track
-
ReSPECT-LM Phase 1 Clinical Trial (FDA IND Approved)
Pediatric Recurrent Ependymoma
Intratumoral
-
-
Pre-FDA IND
Pediatric Recurrent High-Grade GliomaIntratumoral
-
-
Pre-FDA IND
Peritoneal CarcinomatosisIntraperitoneal
-
-
Late-Stage Preclinical
Head & Neck Squamous Cell CarcinomaIntratumoral
-
-
Late-Stage Preclinical

Recurrent Glioblastoma

PLUS THERAPEUTICS has an open FDA-approved IND and an active, enrolling, U.S. multi-center NIH-supported Phase 1/2 clinical trial of 186RNL for patients with recurrent glioblastoma. To learn more about 186RNL, click here.  To learn more about the ReSPECT-GBM Clinical Trial, click here.

Leptomeningeal Metastases

PLUS THERAPEUTICS has an open FDA-approved IND and a pending U.S. multi-center Phase 1 clinical trial of 186RNL for patients with leptomeningeal metastases. To learn more about 186RNL, click here.  To learn more about the ReSPECT-LM Clinical Trial, click here.